Liver Diseases  >>  Cyramza (ramucirumab)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Cyramza (ramucirumab) / Eli Lilly
NCT00627042: Study of IMC-1121B (Ramucirumab) in Participants With Liver Cancer Who Have Not Previously Been Treated With Chemotherapy

Checkmark P2 data
Jun 2010 - Jun 2010: P2 data
Completed
2
42
US
Ramucirumab (IMC-1121B), Ramucirumab, IMC-1121B, LY3009806
Eli Lilly and Company
Hepatocellular Carcinoma
05/11
05/11

Download Options